SCHEMBL810349

SCHEMBL810349

CC(O)c1ccccc1[O]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.42
GABRB2 P47870 2/20 0.42
HTR2C P28335 3/20 0.39
LMNA P02545 3/20 0.39
TSHR P16473 2/20 0.39
PTGS1 P23219 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
HIF1A Q16665 2/20 0.39
FAAH O00519 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
GABRB1 P18505 1/20 0.39
SLC6A2 P23975 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5101318 0.83 GABRA1 (0.50) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL5101317 0.83 GABRA1 (0.50) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL382010 0.83 GABRA1 (0.50) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL396706 0.78 GABRA1 (0.52) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL2544954 0.78 GABRA1 (0.40) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL8274478 0.76 GABRA1 (0.56) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL5907397 0.76 GABRA1 (0.44) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL8274480 0.76 GABRA1 (0.56) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL6055133 0.76 GABRA1 (0.56) GABRA1GABRB2HTR2CLMNATSHR
SCHEMBL588784 0.75 GABRA1 (0.39) GABRA1GABRB2HTR2CLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4622169-A ANTHRAQUINONE OR NAPHTHAQUINONE SUBSTITUTED WITH AMINO GROUP REACTED WITH METAL SALT THE DOW CHEMICAL COMPANY (US) 1986-11-11 US claimed
US-10370536-B2 Resin composition, prepreg, resin sheet, metal foil-clad laminate, and printed wiring board MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2019-08-06 US disclosed
EP-3115418-B1 RESIN COMPOSITION, PREPREG, RESIN SHEET, METAL-FOIL-CLAD LAMINATED PLATE, AND PRINTED WIRING BOARD MITSUBISHI GAS CHEMICAL CO (JP) 2018-05-23 EP disclosed
US-20170158854-A1 RESIN COMPOSITION, PREPREG, RESIN SHEET, METAL-FOIL-CLAD LAMINATED PLATE, AND PRINTED WIRING BOARD MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2017-06-08 US disclosed
EP-3115418-A1 RESIN COMPOSITION, PREPREG, RESIN SHEET, METAL-FOIL-CLAD LAMINATED PLATE, AND PRINTED WIRING BOARD Mitsubishi Gas Chemical Company, Inc. (JP) 2017-01-11 EP disclosed
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
US-7728025-B2 2-heteroaryl-substituted benzimidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed
EP-1273608-B1 FLAME-RETARDANT EPOXY RESIN COMPOSITION, MOLDED OBJECT THEREOF, AND ELECTRONIC PART OTSUKA KAGAKU KK (JP) 2007-07-04 EP disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed
EP-1063252-B1 FLAME-RETARDANT RESIN, COMPOSITION THEREOF, AND PROCESS FOR PRODUCING THE SAME OTSUKA KAGAKU KK (JP) 2005-06-08 EP disclosed
US-6797750-B2 Flame-retardant epoxy resin composition, molded article thereof, and electronic part OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 2004-09-28 US disclosed
US-6632891-B1 Obtained by an ester exchange reaction between the flame retardant phosphazene and the polycarbonate or polyester resin OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 2003-10-14 US disclosed
US-20030114606-A1 A phosphazene compound or polyphosphazenes; fireproofing OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 2003-06-19 US disclosed
EP-1273608-A1 FLAME-RETARDANT EPOXY RESIN COMPOSITION, MOLDED OBJECT THEREOF, AND ELECTRONIC PART OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 2003-01-08 EP disclosed
EP-1063252-A1 FLAME-RETARDANT RESIN, COMPOSITION THEREOF, AND PROCESS FOR PRODUCING THE SAME OTSUKA KAGAKU KABUSHIKI KAISHA (JP) 2000-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 GABRA1 4202/4885GABRB2 4000/4885HTR2C 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.